Eris Lifesciences has reported results for fourth quarter (Q4) and year ended March 31, 2023.
The company has reported 1.31% rise in net profit at Rs 87.84 crore for the quarter under review as compared to Rs 86.71 crore for the same quarter in the previous year. Total income of the company increased by 9.50% at Rs 318.84 crore for Q4FY23 as compared to Rs 291.19 crore for the corresponding quarter previous year.
On consolidated basis, the company has reported 23.13% fall in its net profit at Rs 61.48 crore for fourth quarter ended March 31, 2023 as compared to Rs 79.97 crore for the same quarter in the previous year. However, total income of the company increased by 28.59% at Rs 403.80 crore for Q4FY23 as compared to Rs 314.01 crore for the corresponding quarter previous year.
For the year ended March 31, 2023, the company has reported 4.60% fall in its net profit at Rs 398.01 crore as compared to Rs 417.19 crore for the previous year. However, total income of the company increased by 8.30% at Rs 1,347.99 crore for year under review as compared to Rs 1,244.72 crore for year ended March 31, 2022.
For the year ended March 31, 2023, on the consolidated basis, the company has reported 7.79% fall in its net profit at Rs 374.16 crore as compared to Rs 405.79 crore for the previous year. However, total income of the company increased by 23.53% at Rs 1,696.30 crore for year under review as compared to Rs 1,373.14 crore for year ended March 31, 2022.